Ilan Hadar - Kadimastem External Director
| KDST Stock | ILA 1,189 14.00 1.19% |
Insider
Ilan Hadar is External Director of Kadimastem since 2019.
| Age | 49 |
| Tenure | 5 years |
| Phone | 972 73 797 1600 |
| Web | https://www.kadimastem.com |
Kadimastem Management Efficiency
The company has return on total asset (ROA) of (0.7485) % which means that it has lost $0.7485 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (7.3543) %, meaning that it generated substantial loss on money invested by shareholders. Kadimastem's management efficiency ratios could be used to measure how well Kadimastem manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Abbas Hussain | Teva Pharmaceutical Industries | 54 | |
| Yifat Esq | Kamada | 47 | |
| Jerry Neal | Tower Semiconductor | 74 | |
| Rami Myerson | Elbit Systems | N/A | |
| Amir Weiss | Teva Pharmaceutical Industries | 46 | |
| Kathleen Veit | Teva Pharmaceutical Industries | N/A | |
| Elias MD | Opko Health | 72 | |
| Janet Vergis | Teva Pharmaceutical Industries | 54 | |
| Jon MD | Opko Health | 68 | |
| Arie Gutman | Opko Health | 69 | |
| Eran Nir | Kamada | 51 | |
| Yoav Chelouche | Tower Semiconductor | 66 | |
| Iris Avner | Tower Semiconductor | 54 | |
| Deborah Griffin | Teva Pharmaceutical Industries | N/A | |
| Ronit SatchiFainaro | Teva Pharmaceutical Industries | 46 | |
| Yaacov Kagan | Elbit Systems | N/A | |
| James DeMarco | Opko Health | N/A | |
| Andrew Weil | Teva Pharmaceutical Industries | 52 | |
| Haim Delmar | Elbit Systems | 49 | |
| MBA MBA | Opko Health | 75 | |
| Kare Schultz | Teva Pharmaceutical Industries | 62 | |
Management Performance
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 |
Kadimastem Leadership Team
Elected by the shareholders, the Kadimastem's board of directors comprises two types of representatives: Kadimastem inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kadimastem. The board's role is to monitor Kadimastem's management team and ensure that shareholders' interests are well served. Kadimastem's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kadimastem's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Keren Tzlill, External Director | ||
| Yossi Nizhar, Vice President - Finance | ||
| Ilan Hadar, External Director | ||
| Arik Hasson, Exec Devel | ||
| Yossi BenYossef, Honorary Consultant | ||
| Michal Izrael, VP Diseases | ||
| David Sultan, Independent Director | ||
| Asaf Shiloni, Chief Officer | ||
| Michel Revel, Chief Scientific Officer-Services Provider, Director | ||
| Ram Epstein, Chief Executive Officer, Director | ||
| Joseph Eldor, Director | ||
| Michal Harel, Vice President - Research & Development-ALS & Neurodegenerative Diseases | ||
| Pr MD, Chief CoFounder | ||
| Abraham Meizler, Director | ||
| Eli Opper, Chairman of the Board | ||
| Ziv Ironi, External Director | ||
| Neta Lavon, Vice President - Operations | ||
| Julien Ruggieri, Director | ||
| Arye Hasson, Executive Vice President-Research & Development |
Kadimastem Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kadimastem a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -7.35 | |||
| Return On Asset | -0.75 | |||
| Current Valuation | 38.77 M | |||
| Shares Outstanding | 35.76 M | |||
| Shares Owned By Insiders | 53.72 % | |||
| Shares Owned By Institutions | 8.31 % | |||
| Price To Earning | (167.60) X | |||
| Price To Book | 5.90 X | |||
| EBITDA | (24.48 M) | |||
| Net Income | (26.27 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Kadimastem Stock
Kadimastem financial ratios help investors to determine whether Kadimastem Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kadimastem with respect to the benefits of owning Kadimastem security.